Study of SRF388 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of
SRF388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in
patients with solid tumors.